A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Clinical Efficacy, Safety, and Immunogenicity of a Human Cocaine Vaccine (TA-CD) in the Treatment of Cocaine Dependence

The purpose of this study is to test the efficacy of a newly developed active vaccine against cocaine (TA-CD).

Start Date01 Aug 2010

Sponsor / Collaborator

Baylor College of Medicine

[+8]

100 Clinical Results associated with Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical)

100 Translational Medicine associated with Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical)

100 Patents (Medical) associated with Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical)

Literatures (Medical) associated with Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical)

01 Dec 2021·CARTILAGEQ3 · MEDICINE

The Viability and Anti-Inflammatory Effects of Hyaluronic Acid-Chitlac-Tracimolone Acetonide- β-Cyclodextrin Complex on Human Chondrocytes

Q3 · MEDICINE

Article

Author: Brun, Paola ; Faggian, Alessia ; Elia, Rossella ; Tarricone, Elena ; Ruggieri, Pietro ; Mattiuzzo, Elena ; Pozzuoli, Assunta

Objective To compare the effects of the complex triamcinolone acetonide-hydroxypropyl-β-cyclodextrin (TA-CD) on in vitro inflamed primary human articular chondrocytes in the presence or absence of the mixture hyaluronic acid-Chitlac, a lactose-modified chitosan (HA-CTL). Design Changes in cell viability and pro-inflammatory cytokines gene expression were analyzed in human chondrocytes using an in vitro model of macrophage-mediated inflammation. Human monocytes U937 were differentiated to macrophages by phorbol 12-myristate 13-acetate (PMA) and lipopolysaccharides (LPS). The anti-inflammatory effects of the complex TA-CD and HA-CTL mixture were assessed on chondrocytes exposed for 24 hours to U937 conditioned medium (CM), by quantitative polymerase chain reaction analysis. Results The TA-CD viability was enhanced by the presence of the HA-CTL mixture in chondrocyte cultures. The exposure of cells to CM significantly increased interleukin-1β and interleukin-6 gene expression, and when the complex TA-CD was added to the inflamed cells, gene transcription of cytokines was restored to near baseline values, both in the presence or in the absence of HA-CTL mixture. Conclusion The addition of HA-CTL mixture significantly attenuated cytotoxicity induced by TA and preserved the anti-inflammatory effects, thus confirming the chondroprotective role of the HA-CTL mixture.

01 Jul 2021·Journal of Controlled ReleaseQ1 · MEDICINE

Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration

Q1 · MEDICINE

Article

Author: Lutty, Gerard A ; Bhutto, Imran A ; Kambhampati, Siva P ; Ho, Katie ; Kannan, Rangaramanujam M ; Wu, Tony ; McLeod, D Scott

Inflammation and neovascularization are key pathological events in human age-related macular degeneration (AMD). Activated microglia/macrophages (mi/ma) and retinal pigmented epithelium (RPE) play an active role in every stage of disease progression. Systemic therapies that can target these cells and address both inflammation and neovascularization will broaden the impact of existing therapies and potentially open new avenues for early AMD where there are no viable therapies. Utilizing a clinically relevant rat model of AMD that mirrors many aspects that of human AMD pathological events, we show that systemic hydroxyl-terminated polyamidoamine dendrimer-triamcinolone acetonide conjugate (D-TA) is selectively taken up by the injured mi/ma and RPE (without the need for targeting ligands). D-TA suppresses choroidal neovascularization significantly (by >80%, >50-fold better than free drug), attenuates inflammation in the choroid and retina, by limiting macrophage infiltration in the pathological area, significantly suppressing pro-inflammatory cytokines and pro-angiogenic factors, with minimal side effects to healthy ocular tissue and other organs. In ex vivo studies on human postmortem diabetic eyes, the dendrimer is also taken up into choroidal macrophages. These results suggest that the systemic hydroxyl dendrimer-drugs can offer new avenues for therapies in treating early/dry AMD and late/neovascular AMD alone, or in combination with current anti-VEGF therapies. This hydroxyl dendrimer platform but conjugated to a different drug is undergoing clinical trials for severe COVID-19, potentially paving the way for faster clinical translation of similar compounds for ocular and retinal disorders.

01 Feb 2021·Advanced Therapeutics

Dendrimer‐Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy

Article

Author: Duh, Elia J. ; Lee, Grace ; Zhou, Lingli ; Cho, Hongkwan ; Kannan, Rangaramanujam M. ; Kambhampati, Siva P. ; Xie, Yangyiran ; Hui, Qiaoyan ; Lai, Michael J.

AbstractDiabetic retinopathy (DR) is the leading cause of blindness in working‐age adults. Severe visual loss in DR is primarily due to proliferative diabetic retinopathy, characterized by pathologic preretinal angiogenesis driven by retinal ischemia. Microglia, the resident immune cells of the retina, have emerged as a potentially important regulator of pathologic retinal angiogenesis. Corticosteroids including triamcinolone acetonide (TA), known for their antiangiogenic effects, are used in treating retinal diseases, but their use is significantly limited by side effects including cataracts and glaucoma. Generation‐4 hydroxyl polyamidoamine dendrimer nanoparticles are utilized to deliver TA to activated microglia in the ischemic retina in a mouse model of oxygen‐induced retinopathy (OIR). Following intravitreal injection, dendrimer‐conjugated TA (D‐TA) exhibits selective localization and sustained retention in activated microglia in disease‐associated areas of the retina. D‐TA, but not free TA, suppresses inflammatory cytokine production, microglial activation, and preretinal neovascularization in OIR. In addition, D‐TA, but not free TA, ameliorates OIR‐induced neuroretinal and visual dysfunction. These results indicate that activated microglia are a promising therapeutic target for retinal angiogenesis and neuroprotection in ischemic retinal diseases. Furthermore, dendrimer‐based targeted therapy and specifically D‐TA constitute a promising treatment approach for DR, offering increased and sustained drug efficacy with reduced side effects.

100 Deals associated with Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cocaine-Related Disorders	Phase 2	-	ImmuLogic Pharmaceutical Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00969878 (TA-CD, CTgov)	Phase 2	Cocaine-Related Disorders	300	Placebo Injection (Placebo Injection)	nmyeeyrusr(skkuudhmpe) = gnsvopjvsp gjmhkinvhv (hjrgmeyfmk, bfoqlkshbt - zxkjnpgsey) View more	-	12 Dec 2014
				TA-CD Vaccination (TA-CD Vaccination)	nmyeeyrusr(skkuudhmpe) = bbhbdgdnie gjmhkinvhv (hjrgmeyfmk, rkgpalayyz - xnllssyqtz) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis